/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

MoonLake Immunotherapeutics Share Price Today: Live Updates & Key Insights

MoonLake Immunotherapeutics share price today is $17.05, up -4.54%. The stock opened at $17.41 against the previous close of $17.84, with an intraday high of $17.59 and low of $16.97.

MoonLake Immunotherapeutics Share Price Chart

style
pb-0

MoonLake Immunotherapeutics

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0

MoonLake Immunotherapeutics Share Price Performance

$17.05 -0.0454(-4.54%) MLTX at 13 Mar 2026 02:18 PM Biotechnology
Lowest Today 16.97
Highest Today 17.59
Today’s Open 17.41
Prev. Close 17.84
52 Week High 62.75
52 Week Low 5.95
Day’s Range: Low 16.97 High 17.59
52-Week Range: Low 5.95 High 62.75
1 day return -
1 Week return -6.07
1 month return +7.92
3 month return +18.93
6 month return -68.03
1 year return -54.98
3 year return -25.12
5 year return +62.09
10 year return -

MoonLake Immunotherapeutics Institutional Holdings

Bvf Inc 27.54

D. E. Shaw & Co LP 3.46

Cormorant Asset Management, LLC 2.78

Balyasny Asset Management LLC 2.19

Jupiter Merian Glb Eq AbsRet I USD Acc 1.65

Vivo Capital, LLC 1.39

T. Rowe Price Associates, Inc. 1.15

Two Sigma Investments LLC 1.09

T. Rowe Price Health Sciences 1.04

Nuveen, LLC 0.89

HRT FINANCIAL LLC 0.89

Voleon Capital Management LP 0.70

Ikarian Capital, LLC 0.61

Jump Financial LLC 0.59

CREF Total Global Stock Account R3 0.52

Rhenman Healthcare Equity L/S RC2 SEK 0.51

Rhenman Partners Asset Management AB 0.51

The Goldman Sachs Group Inc 0.51

StemPoint Capital LP 0.49

JPMorgan Chase & Co 0.49

Weiss Asset Management LP 0.46

Schonfeld Strategic Advisors LLC 0.45

Marshall Wace Asset Management Ltd 0.45

Boxer Capital Management, LLC 0.38

CREF Global Equities R3 0.32

International Biotechnology Ord 0.27

Fidelity Select Biotechnology 0.20

Candriam Eqs L Biotech C USD Cap 0.19

Vanguard Strategic Small-Cap Equity Inv 0.16

Vanguard Health Care ETF 0.13

TD Health Sciences - I 0.13

Nomura Healthcare Fund Class I 0.11

iShares ESG Aware MSCI USA Small-Cap ETF 0.09

ALPS Medical Breakthroughs ETF 0.09

JNL Multi-Manager Small Cap Value I 0.08

Granahan Inv Mgt Sm-Cap Core Gr 0.07

Victory Small Cap Stock 0.07

T. Rowe Price Health Sciences Port 0.06

Fidelity Nasdaq Composite Index 0.06

Nuveen ESG Small-Cap ETF 0.05

MoonLake Immunotherapeutics Market Status

Strong Buy: 12

Buy: 4

Hold: 0

Sell: 0

Strong Sell: 0

MoonLake Immunotherapeutics Fundamentals

Market Cap 1279.63 M

PB Ratio 4.2026

PE Ratio 0.0

Enterprise Value 961.37 M

Total Assets 424.43 M

Volume 801644

MoonLake Immunotherapeutics Company Financials

Annual Revenue FY25:null 0.0M, FY24:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:null 0.0M

Annual Profit FY25:null 0.0M, FY24:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M

Annual Net worth FY25:-229099000 -229.1M, FY24:-120680002000 -120680.0M, FY23:-45678004 -45.7M, FY22:-64506051 -64.5M, FY21:-4542654 -4.5M

Quarterly Revenue Q4/2025:null 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q4/2024:101850 0.1M

Quarterly Profit Q4/2025:null 0.0M, Q3/2025:-745000 -0.7M, Q2/2025:-742000 -0.7M, Q1/2025:-378000 -0.4M, Q4/2024:50925 0.1M

Quarterly Net worth Q4/2025:-64206000 -64.2M, Q3/2025:-69729000 -69.7M, Q2/2025:-55220000 -55.2M, Q1/2025:-39944000 -39.9M, Q4/2024:-120606670995 -120606.7M

About MoonLake Immunotherapeutics & investment objective

Company Information MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.

Organisation Biotechnology

Employees 130

Industry Biotechnology

CEO Dr. Jorge Santos da Silva Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow